Virtus Logo


COVID-19 antibody testing
Early proof of concept clinical trials
New therapies for asthma & COPD

Human Studies

Learn more

Virtus’s range of in vitro and in vivo pre-clinical models

Learn more

Virtus team publication track record

Learn more

Virtus can assist in the development of new treatments for asthma and COPD

Learn more

Meet the Virtus team

Learn more

COVID-19 swab and quantitative antibody testing

Learn more
Got any questions? Email or call us on 0207 554 5855


We are delighted to announce the launch of the first publicly available Covid-19 antibody test specifically for the Omicron variant.


Latest from Virtus

#ERSCongress - Precision meets immunology. Nice talk by Prof. Pavord showing that dupilumab reduces AE most impressively in high FeNO, high eos T2 asthmatics.

Could this be restoration of impaired anti-viral immunity?


#ERSCongress – Hot topics: microbiome, infection and host defence. Prof Smits discusses parasites, microbiota and their influence on the immune system.

Is H. polygyrus the next source of T2 cytokine blockers? Watch this space.

#ERS2019 #Asthma #VirTus #ERSTalks

#ERSCongress – In beyond T2 mechanisms in asthma, phages as magic bullets Prof J Simpson: surely the lung immune response is not aimed solely at bacteria but the phages they contain? Phages as a source of inflammation?

#ERS2019 #Asthma #Inflammation #VirTus

#ERSCongress – In beyond T2 mechanisms in asthma, phages as magic bullets by Prof. J Simpson.
Are we heading towards mapping out the respiratory phagome?
#ERS2019 #Asthma #VirTus

#ERSCongress It takes 2 to tango: Prof Nair interesting talk on T cell biology and eos; TH2 cells remain an elusive target. Also, a great overview of potential importance of DR3/TL1a signalling in ILC2 and eosinophilia crosstalk. Surely the next big target in T2 asthma!

#ERSCongress – It takes 2 to tango: Prof HJ Hoffmann gave a great talk on IgE mast cell interactions and possible implications for asthma severity.

#ERS2019 #Asthma #VirTus #ERSTalks

#ERSCongress – It takes 2 to tango: Prof P Bradding discussion on the effects of SABAs on mast cell function. Shows how little we know about the immunomodulatory effects of beta2agonists, both harmful and beneficial.

#ERS2019 #Asthma #COPD #VirTus

More Tweets

Get in touch

Want to find out more how we can help you develop the next block-buster medicine in asthma or COPD? Get in touch.

Our clients

We partner with a range of clients from large pharmaceutical companies to biotechs to assist them in the development of new medicines for respiratory diseases.

Keep Updated With Our Progress

Keep up with the latest results, news and other headlines from Virtus Respiratory Research.

The email address is incorrect
Please agree to our Privacy and Policy
Something went wrong